Hi FHC,
I got the impression management agree with you to some extent. They still aren’t sure whether to pursue the glaucoma option. There is a huge prize if they are right but if they are wrong they waste a lot of resources.
They are trying to find a way to reduce risk. Design a human tissue model to test it first or perhaps like( I think it was )TB was saying get someone else to run the trial.
Eagle.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.34 |
Change
-0.080(5.63%) |
Mkt cap ! $781.5M | |||
| Open | High | Low | Value | Volume |
| $1.42 | $1.42 | $1.34 | $640.8K | 470.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 12164 | $1.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.35 | 96533 | 2 |
View Market Depth
| Last trade - 14.45pm 23/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |